Natural Product (NP) Details
General Information of the NP (ID: NP6920) | |||||
---|---|---|---|---|---|
Name |
Guggulsterone
|
||||
Synonyms |
(Z)-Guggulsterone; Guggulsterone; Z-Guggulsterone; 39025-23-5; 95975-55-6; Guggulsterone E&Z; Guggulsterones Z; GUGGULSTERONE Z; Cis-Guggulsterone; UNII-6CST3U34GN; 6CST3U34GN; (Z)-Pregna-4,17(20)-diene-3,16-dione; (8R,9S,10R,13S,14S,17Z)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione; (17Z)-Pregna-4,17(20)-diene-3,16-dione; Gugulsterone; Pregna-4,17(20)-diene-3,16-dione; (8R,9S,10R,13S,14S,Z)-17-ethylidene-10,13-dimethyl-1,6,7,8,9,10,11,12,13,14,15,17-dodecahydro-3H-cyclopenta[a]phenanthrene-3,16(2H)-dione; Guggulsterone, (Z)-; Pregna-4,17(20)-diene-3,16-dione, (17Z)-; GS; (E&Z)-Guggulsterone; DSSTox_CID_13539; DSSTox_RID_79083; DSSTox_GSID_33539; SCHEMBL141657; CHEMBL410683; DTXSID1033539; BDBM21725; CHEBI:135338; BCP18087; Tox21_202518; MFCD01310757; AKOS015963432; ZINC118912814; (Z)-Guggulsterone, analytical standard; AC-6215; CCG-267610; NCGC00091910-01; NCGC00260067-01; AC-28813; (17Z)-pregna-4,17-diene-3,16-dione; 4,17(20)-trans-Pregnadiene-3,16-dione; CAS-39025-23-5; HY-107738; CS-0029421; S3792; V2228; (Z)-Guggulsterone, >=89% (HPLC), powder; 2-(2-Aminothiazol-3(2H)-yl)-1-phenylethanone; 975G556; BRD-K26674531-001-01-3; Q27264514; UNII-A4PW148END component WDXRGPWQVHZTQJ-OSJVMJFVSA-N; Guggulsterone Z, United States Pharmacopeia (USP) Reference Standard; (1S,2R,10R,11S,14Z,15S)-14-ethylidene-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-ene-5,13-dione
Click to Show/Hide
|
||||
Species Origin | Commiphora mukul ... | Click to Show/Hide | |||
Commiphora mukul | |||||
Disease | Osteoarthritis [ICD-11: FA00-FA05] | Approved | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C21H28O2
|
||||
PubChem CID | |||||
Canonical SMILES |
CC=C1C(=O)CC2C1(CCC3C2CCC4=CC(=O)CCC34C)C
|
||||
InChI |
1S/C21H28O2/c1-4-16-19(23)12-18-15-6-5-13-11-14(22)7-9-20(13,2)17(15)8-10-21(16,18)3/h4,11,15,17-18H,5-10,12H2,1-3H3/b16-4+/t15-,17+,18+,20+,21-/m1/s1
|
||||
InChIKey |
WDXRGPWQVHZTQJ-OSJVMJFVSA-N
|
||||
CAS Number |
CAS 39025-23-5
|
||||
ChEBI ID | |||||
Herb ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | MIA PaCa-2 | CVCL_0428 | Pancreatic ductal adenocarcinoma | Homo sapiens | ||
PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
In-vivo Model | To ceate the subcutaneous xenograft model, mice were subcutaneously inoculated with MiaPaCa-2 cells (1*106cells/mouse) in 1 mL of Matrigel. | |||||
Experimental
Result(s) |
The combination of guggulsterone to gemcitabine enhanced antitumor efficacy through apoptosis induction by suppressing Akt and nuclear factor KappaB activity and by modulating apoptosis-related protein expression in pancreatic cancer. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Farnesoid X-activated receptor (FXR) | Molecule Info | [3] | |
KEGG Pathway | Bile secretion | Click to Show/Hide | ||
Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | Click to Show/Hide | ||
Reactome | Recycling of bile acids and salts | Click to Show/Hide | ||
2 | PPARA activates gene expression | |||
3 | Endogenous sterols | |||
WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | Click to Show/Hide | ||
2 | Nuclear Receptors Meta-Pathway | |||
3 | Farnesoid X Receptor Pathway | |||
4 | Drug Induction of Bile Acid Pathway |